YOUNG KIM: Open Payments
NPI 1417732546 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,916 in 79 payments from 16 companies in 2025. Trend: 2023 $177 · 2024 $1,170 · 2025 $1,916
Food & beverage: $1,916
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $430 |
| Madrigal Pharmaceuticals | 6 | $375 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $252 |
| Janssen Biotech, Inc. | 5 | $217 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| PFIZER INC. | 6 | $113 |
| GENZYME CORPORATION | 4 | $109 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Invivyd Inc | 1 | $33 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, DUPIXENT, RINVOQ, ENTYVIO, LINZESS, SKYRIZI.
Industry payments across MD — which companies pay providers there.
